{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:42:35Z","timestamp":1793659355874,"version":"4.5.1"},"reference-count":69,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Infliximab (IFX) is a recombinant DNA-derived chimeric IgG monoclonal antibody protein that inhibits tumor necrosis factor alpha (TNF-\u03b1). IFX, like other agents derived from foreign proteins, can cause infusion reactions both during and after the infusion. The incidence of infusion reactions ranges between 0% and 15% in pediatric patients. The potential underlying mechanisms for these reactions may include anaphylaxis and anaphylactoid reactions, cytokine release syndrome, serum sickness-like reactions, and the development of antibodies against IFX. Several precautions can help reduce the risk of a new infusion reaction, such as a gradual increase in the infusion rate, scheduled infusions, and administering premedication or immunomodulators alongside IFX. Acute mild to moderate reactions often resolve spontaneously after a temporary cessation of the infusion or reduction in the infusion rate. Strategies like graded dose challenges and premedication can be utilized to prevent recurrence. In cases of severe reactions, desensitization or switching to an alternative biologic may be considered. This article aims to review the most recent guidelines for managing IFX-related infusion reactions in pediatric patients with inflammatory bowel disease (IBD), relying on the best available evidence.<\/jats:p>","DOI":"10.3390\/children11111366","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T03:52:07Z","timestamp":1731297127000},"page":"1366","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Infusion Reactions to Infliximab in Pediatric Patients with Inflammatory Bowel Disease"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2338-1849","authenticated-orcid":false,"given":"Rajmohan","family":"Dharmaraj","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Pediatrics, University of New Mexico, Albuquerque, NM 87131, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess Pei","family":"Lemon","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Pediatrics, University of New Mexico, Albuquerque, NM 87131, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Elmaoued","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Pediatrics, University of New Mexico, Albuquerque, NM 87131, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Orlando","family":"Castillo","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Pediatrics, University of New Mexico, Albuquerque, NM 87131, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan","family":"Alkhouri","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Pediatrics, University of New Mexico, Albuquerque, NM 87131, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,10]]},"reference":[{"key":"ref_1","unstructured":"Janssen Biotech, Inc. (2024, April 11). Remicade (Infliximab) Prescribing Information. Available online: https:\/\/www.remicade.com\/index.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/MPG.0000000000002815","article-title":"Safety of Rapid Infliximab Infusions in Children: A Systematic Review","volume":"71","author":"Daams","year":"2020","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_3","unstructured":"(2024, April 11). United States Food and Drug Administration Purple Book. Database of Licensed Biologic Products, Available online: https:\/\/purplebooksearch.fda.gov\/results?query=infliximab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/MPG.0000000000001643","article-title":"Induction therapy with biosimilar infliximab in children with Crohn disease","volume":"65","author":"Meglicka","year":"2017","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/MPG.0000000000002011","article-title":"Use of infliximab biosimilar versus originator in a pediatric United Kingdom Inflammatory Bowel Disease Induction Cohort","volume":"67","author":"Chanchlani","year":"2018","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/ecco-jcc\/jjv233","article-title":"Switching between infliximab originator and biosimilar in pediatric patients with inflammatory bowel disease: Preliminary observations","volume":"10","author":"Sieczkowska","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/ibd\/izx047","article-title":"Long-term outcomes after switching to CT-P13 in pediatric-onset inflammatory bowel disease: A single center prospective observational study","volume":"24","author":"Kang","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/MPG.0000000000002141","article-title":"Use of biosimilars in pediatric inflammatory bowel disease: An updated position statement of the Pediatric IBD Porto Group of ESPGHAN","volume":"68","author":"Assa","year":"2019","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00228-019-02715-z","article-title":"Premedication with intravenous steroids does not influence the incidence of infusion reactions following infliximab infusions in pediatric inflammatory bowel disease patients\u2014A case-control study","volume":"75","author":"Meester","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s10620-018-5319-6","article-title":"Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting","volume":"64","author":"Checkley","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1111\/jcpt.13779","article-title":"Rapid infusion of infliximab biosimilars and the incidence and severity of infusion-related reactions in patients with inflammatory bowel disease","volume":"47","author":"Rusch","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/MPG.0000000000003402","article-title":"Rapid infliximab biosimilar infusion in children with inflammatory bowel disease","volume":"74","author":"Nachreiner","year":"2022","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: The ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s disease","volume":"350","author":"Sands","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","article-title":"Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn\u2019s disease","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000080075","article-title":"Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital","volume":"70","author":"Seiderer","year":"2004","journal-title":"Digestion"},{"key":"ref_20","first-page":"502","article-title":"Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab","volume":"38","author":"Miele","year":"2004","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_21","first-page":"A614","article-title":"Short and long term safety of Remicade in Crohn\u2019s disease and rheumatoid arthritis","volume":"122","author":"Louis","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_22","first-page":"250","article-title":"Monoclonal antibodies, immunogenicity, and associated infusion reactions","volume":"72","author":"Cheifetz","year":"2005","journal-title":"Mt. Sinai J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1365-2036.2006.03026.x","article-title":"Successful induction of tolerance to infliximab in patients with Crohn\u2019s disease and prior severe infusion reactions","volume":"24","author":"Duburque","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.anai.2014.02.001","article-title":"Detection of IgE binding component to infliximab in a patient with infliximab-induced anaphylaxis","volume":"112","author":"Hwang","year":"2014","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00054725-200102000-00005","article-title":"Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn\u2019s disease patients with prior anaphylactic reaction","volume":"7","author":"Puchner","year":"2001","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/00007890-198904000-00008","article-title":"Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients","volume":"47","author":"Abramowicz","year":"1989","journal-title":"Transplantation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody [rituximab, IDEC-C2B8]","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/ACI.0b013e3283464bcd","article-title":"Immediate adverse reactions to biologicals: From pathogenic mechanisms to prophylactic management","volume":"11","author":"Vultaggio","year":"2011","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.crohns.2012.06.024","article-title":"The complexity of adverse side-effects to biological agents","volume":"7","author":"Aubin","year":"2013","journal-title":"J. Crohns Colitis"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1586\/eci.10.90","article-title":"Acute infusion reactions induced by monoclonal antibody therapy","volume":"7","author":"Maggi","year":"2011","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2133.2005.06648.x","article-title":"Cytokine profiles during infliximab monotherapy in psoriatic arthritis","volume":"153","author":"Mastroianni","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/1529-0131(200107)44:7<1717::AID-ART299>3.0.CO;2-C","article-title":"Serum sickness secondary to treatment with the murine\u2013human chimeric antibody IDEC-C2B8 (rituximab)","volume":"44","author":"Mannik","year":"2001","journal-title":"Arthritis Rheum."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/j.1572-0241.2002.05784.x","article-title":"Infliximab retreatment in adults and children with Crohn\u2019s disease: Risk factors for the development of delayed severe systemic reaction","volume":"97","author":"Kugathasan","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"ref_34","first-page":"A731","article-title":"Delayed hypersensitivity to infliximab [Remicade] re-infusion after a 2\u20134 year interval without treatment","volume":"116","author":"Hanauer","year":"1999","journal-title":"Gastroenterology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn\u2019s disease: A randomized controlled trial","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.gtc.2006.09.006","article-title":"Infusion reactions and their management","volume":"35","author":"Mayer","year":"2006","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ygh2.363","article-title":"High prevalence of antibodies to infliximab and their relation to clinical outcomes in inflammatory bowel disease patients","volume":"1","author":"Tun","year":"2019","journal-title":"GastroHep"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/jpn3.12041","article-title":"Effectiveness of strategies to suppress antibodies to infliximab in pediatric inflammatory bowel disease","volume":"78","author":"Jagt","year":"2024","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1*05 Carriage Associated with Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn\u2019s Disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","article-title":"The incidence and management of infusion reactions to infliximab: A large center experience","volume":"98","author":"Cheifetz","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.anai.2023.09.015","article-title":"Anaphylaxis: A 2023 practice parameter update","volume":"132","author":"Golden","year":"2024","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/apt.12389","article-title":"Meta-analysis: Rapid infliximab infusions are safe","volume":"38","author":"Neef","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.crohns.2013.08.004","article-title":"Tolerability of one hour 10 mg\/kg infliximab infusions in inflammatory bowel diseases: A prospective multicenter cohort study","volume":"8","author":"Babouri","year":"2014","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1517\/14712598.2014.866649","article-title":"Safety and cost benefit of an accelerated infliximab infusion protocol in the treatment of ambulatory patients with inflammatory bowel diseases","volume":"14","author":"Saxena","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/01.MIB.0000158166.88238.ea","article-title":"Premedication and infusion reactions with infliximab: Results from a pediatric inflammatory bowel disease consortium","volume":"11","author":"Jacobstein","year":"2005","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1097\/MIB.0000000000001259","article-title":"Rapid infliximab infusion in children with inflammatory bowel disease: A multicenter North American experience","volume":"23","author":"Dykes","year":"2017","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Szymanska, E., Dadalski, M., Sieczkowska-Golub, J., Jarzebicka, D., Meglicka, M., Osiecki, M., Wiernicka, A., Lebensztejn, D.M., Korczowski, B., and Kierkus, J. (2021). Premedication does not influence the incidence of infliximab infusion reactions in pediatric patients with inflammatory bowel disease\u2014A single center case\u2013control study. J. Clin. Med., 10.","DOI":"10.3390\/jcm10143177"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/SGA.0000000000000592","article-title":"The effectiveness of methylprednisolone as a premedication among the pediatric population for preventing infusion-related reactions to infliximab","volume":"44","author":"Cares","year":"2021","journal-title":"Gastroenterol. Nurs."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/ibd\/izy093","article-title":"Evaluation of rapid vs standard infliximab infusions in the pediatric population","volume":"24","author":"Rozette","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/acr.20246","article-title":"Prevention of acute adverse events related to infliximab infusions in pediatric patients","volume":"62","author":"Lahdenne","year":"2010","journal-title":"Arthritis Care Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clim.2005.07.010","article-title":"Clinical and biological consequences of immunization to infliximab in pediatric Crohn\u2019s disease","volume":"118","author":"Candon","year":"2006","journal-title":"Clin. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/MEG.0b013e3283081afe","article-title":"Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease","volume":"21","author":"Clare","year":"2009","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn\u2019s disease: A meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1111\/j.1572-0241.2002.07093.x","article-title":"Infliximab in the treatment of Crohn\u2019s disease: A user\u2019s guide for clinicians","volume":"97","author":"Sandborn","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2165\/00003495-200464160-00004","article-title":"Managing immunogenic responses to infliximab: Treatment implications for patients with Crohn\u2019s disease","volume":"64","author":"Han","year":"2004","journal-title":"Drugs"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bpg.2008.12.005","article-title":"Serum sickness, encephalitis and other complications of anti-cytokine therapy","volume":"23","author":"Vermeire","year":"2009","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.gtc.2014.05.002","article-title":"Miscellaneous adverse events with biologic agents (excludes infection and malignancy)","volume":"43","author":"Feuerstein","year":"2014","journal-title":"Gastroenterol. Clin. North Am."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.crohns.2009.12.001","article-title":"A decade of infliximab: The Austrian evidence-based consensus on the safe use of infliximab in inflammatory bowel disease","volume":"4","author":"Miehsler","year":"2010","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/ecco-jcc\/jjv096","article-title":"Infliximab-related infusion reactions: Systematic review","volume":"9","author":"Lichtenstein","year":"2015","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn\u2019s disease: The Mayo Clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaip.2013.11.007","article-title":"Indications, protocols, and outcomes of drug desensitizations for chemotherapy and monoclonal antibodies in adults and children","volume":"2","author":"Hong","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.jaci.2009.09.009","article-title":"Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment","volume":"124","author":"Brennan","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0761-8425(05)85477-4","article-title":"Desensitization to infliximab in patients with Crohn\u2019s disease","volume":"22","author":"Lelong","year":"2005","journal-title":"Rev. Mal. Respir."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00042737-200406000-00018","article-title":"Severe anaphylactic reaction to infliximab: Successful treatment with adalimumab\u2014Report of a case","volume":"16","author":"Stallmach","year":"2004","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.3748\/wjg.v13.i16.2328","article-title":"Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: An open-label study","volume":"13","author":"Laclotte","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1365-2036.2010.04531.x","article-title":"Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab","volume":"33","author":"Taxonera","year":"2011","journal-title":"Aliment. Pharmacol. Ther."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/11\/11\/1366\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:29:47Z","timestamp":1760113787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/11\/11\/1366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,10]]},"references-count":69,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["children11111366"],"URL":"https:\/\/doi.org\/10.3390\/children11111366","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,10]]}}}